Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

Naval Daver, Aditi Shastri, Tapan Kadia, Alfonso Quintas-Cardama, Elias Jabbour, Marina Konopleva, Susan O'Brien, Sherry Pierce, Lingsha Zhou, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0. mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5. mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.

Original languageEnglish (US)
Pages (from-to)1440-1444
Number of pages5
JournalLeukemia Research
Volume37
Issue number11
DOIs
StatePublished - Nov 2013
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Anemia
Neutropenia
Appointments and Schedules
Hemoglobins
pomalidomide

Keywords

  • Anemia
  • Myelofibrosis
  • Pomalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Daver, N., Shastri, A., Kadia, T., Quintas-Cardama, A., Jabbour, E., Konopleva, M., ... Verstovsek, S. (2013). Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leukemia Research, 37(11), 1440-1444. https://doi.org/10.1016/j.leukres.2013.07.007

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. / Daver, Naval; Shastri, Aditi; Kadia, Tapan; Quintas-Cardama, Alfonso; Jabbour, Elias; Konopleva, Marina; O'Brien, Susan; Pierce, Sherry; Zhou, Lingsha; Cortes, Jorge; Kantarjian, Hagop; Verstovsek, Srdan.

In: Leukemia Research, Vol. 37, No. 11, 11.2013, p. 1440-1444.

Research output: Contribution to journalArticle

Daver, N, Shastri, A, Kadia, T, Quintas-Cardama, A, Jabbour, E, Konopleva, M, O'Brien, S, Pierce, S, Zhou, L, Cortes, J, Kantarjian, H & Verstovsek, S 2013, 'Modest activity of pomalidomide in patients with myelofibrosis and significant anemia', Leukemia Research, vol. 37, no. 11, pp. 1440-1444. https://doi.org/10.1016/j.leukres.2013.07.007
Daver, Naval ; Shastri, Aditi ; Kadia, Tapan ; Quintas-Cardama, Alfonso ; Jabbour, Elias ; Konopleva, Marina ; O'Brien, Susan ; Pierce, Sherry ; Zhou, Lingsha ; Cortes, Jorge ; Kantarjian, Hagop ; Verstovsek, Srdan. / Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. In: Leukemia Research. 2013 ; Vol. 37, No. 11. pp. 1440-1444.
@article{565d4dcfb6b744c4bb421465993d5a6a,
title = "Modest activity of pomalidomide in patients with myelofibrosis and significant anemia",
abstract = "We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0. mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5. mg/day continuously. Three patients (10{\%}) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20{\%}) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.",
keywords = "Anemia, Myelofibrosis, Pomalidomide",
author = "Naval Daver and Aditi Shastri and Tapan Kadia and Alfonso Quintas-Cardama and Elias Jabbour and Marina Konopleva and Susan O'Brien and Sherry Pierce and Lingsha Zhou and Jorge Cortes and Hagop Kantarjian and Srdan Verstovsek",
year = "2013",
month = "11",
doi = "10.1016/j.leukres.2013.07.007",
language = "English (US)",
volume = "37",
pages = "1440--1444",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

AU - Daver, Naval

AU - Shastri, Aditi

AU - Kadia, Tapan

AU - Quintas-Cardama, Alfonso

AU - Jabbour, Elias

AU - Konopleva, Marina

AU - O'Brien, Susan

AU - Pierce, Sherry

AU - Zhou, Lingsha

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2013/11

Y1 - 2013/11

N2 - We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0. mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5. mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.

AB - We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0. mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5. mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.

KW - Anemia

KW - Myelofibrosis

KW - Pomalidomide

UR - http://www.scopus.com/inward/record.url?scp=84886771903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886771903&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.07.007

DO - 10.1016/j.leukres.2013.07.007

M3 - Article

VL - 37

SP - 1440

EP - 1444

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11

ER -